Randomized, Double-Blind, Placebo-Controlled Phase III Clinical Trial For Evaluation of Efficacy and Safety of SARS-CoV-2 Vaccine (Vero Cell), Inactivated
Latest Information Update: 28 May 2024
At a glance
- Drugs SARS-COV-2 vaccine-inactivated-Sinovac-Biotech (Primary)
- Indications COVID 2019 infections
- Focus Registrational; Therapeutic Use
- 23 May 2024 Status changed from active, no longer recruiting to completed.
- 07 Jun 2022 Planned primary completion date changed from 17 May 2022 to 30 Jun 2022.
- 10 May 2022 Planned End Date changed from 15 Apr 2022 to 31 Aug 2022.